U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H19N5O
Molecular Weight 369.4192
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GALUNISERTIB

SMILES

CC1=CC=CC(=N1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(N)=O

InChI

InChIKey=IVRXNBXKWIJUQB-UHFFFAOYSA-N
InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)

HIDE SMILES / InChI
Molecular Formula C22H19N5O
Molecular Weight 369.4192
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Galunisertib is a potent inhibitor of TGF beta type 1 receptor. The drug is under clinical development for the treatment of different cancers: pancreatic, hepatocellular, breast, rectal, prostate etc. and reached phase 2/3 in patients with myelodysplastic syndromes.

Originator

Eli Lilly
239
Curator's Comment: # Eli Lilly

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 56.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
800 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25529192/
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GALUNISERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
990 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25529192/
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GALUNISERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2930 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25529192/
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GALUNISERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3730 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25529192/
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GALUNISERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25529192/
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GALUNISERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25529192/
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GALUNISERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
36%
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28436712
GALUNISERTIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY116175
https://www.001chemical.com/chem/search?q=DY116175
1PlusChem LLC
1P003497
https://www.1pchem.com/search?query=1P003497
A2B Chem
AB44683
http://a2bchem.com/prod/AB44683
AA Blocks
AA0033PR
http://aablocks.com/goods/Goods/detail?id=AA0033PR
AChemBlock
10348
http://www.achemblock.com/catalogsearch/result/?q=10348
AK Scientific
2180AH
https://aksci.com/item_detail.php?cat=2180AH
AK Scientific
X7574
https://aksci.com/item_detail.php?cat=X7574
Ambeed
A150887
http://www.ambeed.com/search/Search.html?keyword=A150887
Angene
AGN-PC-0MYLJ5
http://www.angenechemical.com/productshow/AGN-PC-0MYLJ5.html
AOBIOUS INC
AOB87326
http://aobious.com/aobious/search?search_query=AOB87326
ApexBio Technology
A8348
https://www.apexbt.com/catalogsearch/result/?q=A8348
AstaTech
87769
http://astatechinc.com/CPSResult.php?CRNO=87769
Axon MedChem
1491
https://www.axonmedchem.com/product/1491
BLD Pharm
BD263065
http://www.bldpharm.com/search/Search.html?keyword=BD263065
BOC Sciences
700874-72-2
http://www.bocsci.com/description.asp?cas=700874-72-2
Capot Chemical
22590
https://www.capotchem.com/search.do?q=22590
Cayman Chemical
15312
http://www.caymanchem.com/app/template/Product.vm/catalog/15312
Chem Scene
CS-0474
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0474
ChemShuttle
104837
https://www.chemshuttle.com/catalogsearch/result/?q=104837
Combi-Blocks
QM-0902
http://www.combi-blocks.com/cgi-bin/find.cgi?QM-0902
eMolecules
36366152
https://orderbb.emolecules.com/search/#?query=36366152
eMolecules
56967761
https://orderbb.emolecules.com/search/#?query=56967761
eNovation Chemicals
D572822
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D572822&searchbtn.x=0&searchbtn.y=0
Excenen
EX-A009
http://www.excenen.com/searchresultlist.php?id=EX-A009
Fluorochem
340506
http://www.fluorochem.co.uk/Products/Product?code=340506
Hairui
GASA043
http://www.hairuichem.com/en/product/search.do?q=GASA043
KeyOrganics
AS-42940
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-42940
Lab Network
LN01291167
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01291167
Lab Seeker
SC-85597
http://www.labseeker.com/search.php?keywords=SC-85597&category=0
LabSeeker
SC-85597
http://www.labseeker.com/search.php?keywords=SC-85597&category=0
Matrix Scientific
131678
http://www.matrixscientific.com/131678.html
mcule
MCULE-2583993241
https://mcule.com/MCULE-2583993241/
MedChem Express
HY-13226
https://www.medchemexpress.com/search.html?q=HY-13226&ft=&fa=&fp=
Molcore
MC116175
http://www.molcore.com/CatMC116175.html
Molnova
M15689
https://www.molnova.com/en/serch-list.html?keywords=M15689
MolPort
MolPort-020-000-498
https://www.molport.com/shop/molecule-link/MolPort-020-000-498
MuseChem
I004629
https://www.musechem.com/product/I004629.html
Ryan Scientific
Saxagliptin_hydrate
https://ryansci.com/products?q=Saxagliptin_hydrate&list_q=&search_type=exact
Selleck Chemicals
S2230
http://www.selleckchem.com/search.html?searchDTO.searchParam=S2230
ShangHai Biochempartner
BCP000261
http://www.biochempartner.com/search_BCP000261
ShangHai Biochempartner
BCP02173
http://www.biochempartner.com/search_BCP02173
TargetMol
T2510
https://www.targetmol.com/search?keyword=T2510
W&J PharmaChem
50C1239122
http://wjpharmachem.com/new/searcht.php?keyword=50C1239122
Wonderchem
WD03ZLQ
http://www.wonder-chem.com/search.html?text=WD03ZLQ
PubMed

PubMed

TitleDatePubMed
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
2017-02-01
Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
2016-08-08
Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes.
2016-03-15
Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.
2015-11
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
2015-08-28
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
2015-04
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
2015
Patents

Patents

20060040983
2

Sample Use Guides

In Vivo Use Guide
Patients receive 150 milligrams of galunisertib, given orally twice daily for 14 days followed by 14 days with no study drug (28 day cycles).
Route of Administration: Oral
In Vitro Use Guide
JHH6, SK-HEP1, SK-Sora, HepG2, Hep3B, and HuH7 cells were simultaneously exposed to 0.1, 1, 10, and 100 uM galunisertib with 5 uM sorafenib in presence of TGF-beta for 72 hours.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:10:21 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:21 GMT 2025
Record UNII
3OKH1W5LZE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
galunisertib [INN]
Preferred Name English
GALUNISERTIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
6-QUINOLINECARBOXAMIDE, 4-(5,6-DIHYDRO-2-(6-METHYL-2-PYRIDINYL)-4H-PYRROLO(1,2-B)PYRAZOL-3-YL)-
Systematic Name English
LY2157299
Code English
Galunisertib [WHO-DD]
Common Name English
4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
Systematic Name English
LY-2157299
Code English
6-QUINOLINECARBOXAMIDE, 4-(5,6-DIHYDRO-2-(6-METHYL-2-PYRIDINYL)-4H-PYRROLO(1,2-B)PYRAZOL-3-YL)-)
Common Name English
GALUNISERTIB [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
FDA ORPHAN DRUG 378712
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
FDA ORPHAN DRUG 389412
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
NCI_THESAURUS C61074
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
Code System Code Type Description
DRUG BANK
DB11911
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID00220362
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
FDA UNII
3OKH1W5LZE
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
CHEBI
137064
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
WIKIPEDIA
Galunisertib
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
CAS
700874-72-2
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
INN
9768
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL2364611
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
SMS_ID
100000151897
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
USAN
ZZ-52
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
NCI_THESAURUS
C116891
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
EVMPD
SUB126321
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
PUBCHEM
10090485
Created by admin on Mon Mar 31 18:10:21 GMT 2025 , Edited by admin on Mon Mar 31 18:10:21 GMT 2025
PRIMARY
Related Record Type Details
Structure of GALUNISERTIB MONOHYDRATE
SOLVATE->ANHYDROUS
Structure of GALUNISERTIB MONOHYDRATE
SALT/SOLVATE -> PARENT
TGF-BETA RECEPTOR TYPE-1
TARGET -> INHIBITOR
Related Record Type Details
Structure of GALUNISERTIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966